KROS 8-K: SEC filing

Filed with the SEC on Nov 5, 2026 · accession 0001664710-26-000067

KROS filed a 8-K (current report) with the SEC on Nov 5, 2026. Keros Therapeutics furnished a corporate presentation (Exhibit 99.1) on Form 8-K, highlighting its clinical-stage pipeline including rinvatercept (KER-065) for Duchenne muscular dystrophy and ALS, elritercept (KER-050) for myelodysplastic syndromes and myelofibrosis, and KER-206 for bone loss… The stock moved -12.7% by the first close after the filing.

Summary of the filing

Keros Therapeutics furnished a corporate presentation (Exhibit 99.1) on Form 8-K, highlighting its clinical-stage pipeline including rinvatercept (KER-065) for Duchenne muscular dystrophy and ALS, elritercept (KER-050) for myelodysplastic syndromes and myelofibrosis, and KER-206 for bone loss disorders.

For details, click here →How to read a 8-K →

Key details

IssuerKeros Therapeutics, Inc.

How KROS stock reacted

Close before

$10.83

Nov 4, 2026

First close after

-12.74%

$9.45

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for KROS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for KROS?

Click here

Frequently asked questions

What did KROS file with the SEC on Nov 5, 2026?

KROS filed a 8-K (SEC filing). Keros Therapeutics furnished a corporate presentation (Exhibit 99.1) on Form 8-K, highlighting its clinical-stage pipeline including rinvatercept (KER-065) for Duchenne muscular dystrophy and ALS, elritercept (KER-050) for myelodysplastic syndromes and myelofibrosis, and KER-206 for bone loss disorders.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did KROS stock react to this filing?

KROS closed at $10.83 before the filing and $9.45 on Nov 5, 2026 (-12.74%).

Other KROS SEC filings

Get alerts when KROS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

KROS overview KROS analysis KROS news Latest SEC filings